{"preliminary_commentary":{"by_channel":{"youtube":72,"podcast":35,"x_thread":32,"x_video":4,"bluesky_thread":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04739761\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["trastuzumab deruxtecan"]],"indication":"previously treated advanced/metastatic HER2-positive breast cancer","name":"DESTINY-Breast12","nct_id":"NCT04739761","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=destiny-breast12-nct04739761. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"DESTINY-B12","arms":[{"description":"Participants with or without BM at baseline will receive intravenous (IV) T-DXd, 5.4 mg/kg, every 3 weeks (21-day cycle) until Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) defined radiological progression outside central nervous system, unacceptable toxicity, withdrawal of consent, or another criterion for discontinuation is met.","label":"Trastuzumab Deruxtecan","type":"EXPERIMENTAL"}],"collaborators":["Daiichi Sankyo"],"completion_date":{"date":"2027-05-26","type":"ESTIMATED"},"conditions":["Breast Cancer"],"enrollment":{"count":506,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Trastuzumab Deruxtecan","otherNames":["fam-trastuzumab deruxtecan-nxki"],"type":"DRUG"}],"last_update":"2026-08-11","lead_sponsor":"AstraZeneca","official_title":"An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously Treated Advanced/Metastatic HER2-Positive Breast Cancer (DESTINY-Breast12)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2024-02-08","type":"ACTUAL"},"primary_outcomes":[{"measure":"Objective Response Rate (ORR) in Cohort 1 (Participants Without Brain Metastasis at Baseline)","timeFrame":"From first dose (Day 1) to progression of disease (up to 2 years 7 months)"},{"measure":"Progression-free Survival (PFS) Rate at 12 Months in Cohort 2 (Participants With Brain Metastasis at Baseline)","timeFrame":"At 12 months"}],"references":[{"citation":"Harbeck N, Ciruelos E, Jerusalem G, Muller V, Niikura N, Viale G, Bartsch R, Kurzeder C, Higgins MJ, Connolly RM, Baron-Hay S, Gion M, Guarneri V, Bianchini G, Wildiers H, Escriva-de-Romani S, Prahladan M, Bridge H, Kuptsova-Clarkson N, Scotto N, Verma S, Lin NU; DESTINY-Breast12 study group. Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial. Nat Med. 2024 Dec;30(12):3717-3727. doi: 10.1038/s41591-024-03261-7. Epub 2024 Sep 13.","pmid":"39271844","type":"DERIVED"}],"start_date":{"date":"2021-06-22","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer","url":"https://clinicaltrials.gov/study/NCT04739761"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/destiny-breast12-nct04739761"}